

Pfizer's Centers for Therapeutic Innovation

Helpful Tips for Biotherapeutic Pre-Proposals

Pfizer's Centers for Therapeutic Innovation (CTI) collaborates with academic investigators to accelerate concepts into potential breakthrough therapies for patients. What does Pfizer consider when evaluating a large molecule pre-proposal?

KEY CONSIDERATIONS

What do Pfizer scientists look for when evaluating large molecule pre-proposals?*


Large molecule accessibility

Assay compatibility



Ease of target protein production

Tool reagent availability



*When evaluating proposals for collaborative projects, Pfizer considers many factors including but not limited to these criteria

BIO-THERAPEUTIC SUITABILITY

Pfizer scientists broadly categorize targets by location, which helps to evaluate the most suitable modality for targeting. Key for a biotherapeutic target is accessibility.

Extracellular/secreted



Extracellular targets such as soluble factors and cell surface receptors are usually suited to large molecule approaches. Modalities include antibodies, fusion proteins & bi/tri-specifics for multi-target & effector function engagement, or immune activation.

Membrane bound



Historically, GPCRs and ion channels have been more effectively targeted with small molecules. However, advances in complex expression systems have enabled some success at this difficult target class & may provide an option where specificity is challenging.



TOOL REAGENTS

Tool antibodies or reagent proteins can be instrumental in helping optimize assays and serve as starting points for drug discovery campaigns. Whether publicly available or discovered from your in-lab efforts, Pfizer scientists can help to profile existing tools and use this understanding to drive molecular optimization or *de novo* antibody discovery efforts.



SCREENING READY ASSAY

Having a disease-relevant biochemical or cellular assay ready and available is one of the primary means to accelerate the drug discovery process. Collaborators can work with CTI to transfer protein reagents and tool antibodies allowing for assay optimization ahead of any *de novo* screening campaigns.



TARGET ANTIGEN SOURCES

Programs can be rapidly initiated if a suitable source of target antigen is available. This may represent relevant primary cell lines positive and negative for endogenous target, or recombinant cell lines overexpressing the target of interest.

If you have any questions about the pre-proposal process please ask your technology transfer representative to put you in touch with Pfizer.

